Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehrdad Abedi

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Blood|July 11, 2014
Treatment of chronic graft-versus-host disease with bortezomibChien-Chun Steven Pai, Mingyi Chen, Annie Mirsoian, et al.
Cell Stem Cell|June 3, 2018
CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine ChallengesCatriona H M Jamieson, Maria T Millan, Abla A Creasey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2012
IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantationKai Sun, Hui-Hua Hsiao, Minghui Li, et al.
The Prostate|June 22, 2016
Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical ResponseRichard P Junghans, Qiangzhong Ma, Ritesh Rathore, et al.
Experimental Hematology|February 7, 2006
Bone marrow production of lung cells: the impact of G-CSF, cardiotoxin, graded doses of irradiation, and subpopulation phenotypeJason M Aliotta, Patrick Keaney, Michael Passero, et al.
Ophthalmology Science|February 16, 2026
Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and FeasibilitySusanna S Park, Jennifer McCormack, Dagmar Salazar, et al.
Human Vaccines & Immunotherapeutics|September 12, 2025
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survivalDaniela A Bota, David E Piccioni, Christopher M Duma, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 14, 2022
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessmentDaniela A Bota, Thomas H Taylor, David E Piccioni, et al.
Haematologica|January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
Leukemia Research|June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer centerTamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Blood|July 11, 2014
Treatment of chronic graft-versus-host disease with bortezomibChien-Chun Steven Pai, Mingyi Chen, Annie Mirsoian, et al.
Cell Stem Cell|June 3, 2018
CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine ChallengesCatriona H M Jamieson, Maria T Millan, Abla A Creasey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2012
IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantationKai Sun, Hui-Hua Hsiao, Minghui Li, et al.
The Prostate|June 22, 2016
Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical ResponseRichard P Junghans, Qiangzhong Ma, Ritesh Rathore, et al.
Experimental Hematology|February 7, 2006
Bone marrow production of lung cells: the impact of G-CSF, cardiotoxin, graded doses of irradiation, and subpopulation phenotypeJason M Aliotta, Patrick Keaney, Michael Passero, et al.
Ophthalmology Science|February 16, 2026
Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and FeasibilitySusanna S Park, Jennifer McCormack, Dagmar Salazar, et al.
Human Vaccines & Immunotherapeutics|September 12, 2025
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survivalDaniela A Bota, David E Piccioni, Christopher M Duma, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 14, 2022
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessmentDaniela A Bota, Thomas H Taylor, David E Piccioni, et al.
Haematologica|January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
Leukemia Research|June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer centerTamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.
Pageof 7